Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000217582 | SCV000275703 | uncertain significance | Hereditary cancer-predisposing syndrome | 2015-05-08 | criteria provided, single submitter | clinical testing | The c.-2A>T variant is located in the 5' untranslated region (5’ UTR) of the NF1 gene. This variant results from an A to T substitution 2 bases upstream from the first translated codon. Although this alteration is near the initiation codon, it does not disrupt the key nucleotides of theKozak motif known to modulate translation initiation (KozakM, Cell 1986 Jan; 44(2):283-92). This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 5109 samples (10218 alleles) with coverage at this position.To date, this alteration has been detected with an allele frequency of approximately 0.002% (greater than 55000 alleles tested) in our clinical cohort.<span style="font-family:arial,sans-serif">Since supporting evidence is limited at this time, the clinical significance of this variant remains unclear. |
Ambry Genetics | RCV004558521 | SCV005047654 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2024-03-08 | criteria provided, single submitter | clinical testing | The c.-2A>T variant is located in the 5' untranslated region (5’ UTR) of the NF1 gene. This variant results from an A to T substitution 2 bases upstream from the first translated codon. This nucleotide position is highly conserved in available vertebrate species. Based on the available evidence, the clinical significance of this alteration remains unclear. |